In Response to Continuation of Lorlatinib Beyond Progressive Disease. Ignatius Ou SH. J Thorac Oncol 2022;17:e86-e88.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ignatius Ou SH. In Response to Continuation of Lorlatinib Beyond Progressive Disease. J Thorac Oncol 2022;17:e86-e88.
PMID: 36031299